Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Operating Expenses: 2013-2025

Historic Other Operating Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to $14.9 million.

  • Ocular Therapeutix's Other Operating Expenses rose 22.48% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year increase of 26.73%. This contributed to the annual value of $47.2 million for FY2024, which is 3.02% up from last year.
  • As of Q3 2025, Ocular Therapeutix's Other Operating Expenses stood at $14.9 million, which was down 5.17% from $15.7 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Other Operating Expenses high stood at $15.7 million for Q2 2025, and its period low was $9.0 million during Q1 2021.
  • Over the past 3 years, Ocular Therapeutix's median Other Operating Expenses value was $12.1 million (recorded in 2024), while the average stood at $12.6 million.
  • Per our database at Business Quant, Ocular Therapeutix's Other Operating Expenses surged by 56.18% in 2021 and then declined by 7.91% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Other Operating Expenses (Quarterly) stood at $10.2 million in 2021, then grew by 12.69% to $11.5 million in 2022, then fell by 7.91% to $10.6 million in 2023, then increased by 13.54% to $12.1 million in 2024, then increased by 22.48% to $14.9 million in 2025.
  • Its Other Operating Expenses stands at $14.9 million for Q3 2025, versus $15.7 million for Q2 2025 and $15.4 million for Q1 2025.